Novartis’ Ilaris provides hope for Periodic Fever Syndrome patients
27 April 2016 | By Mandy Parrett, Editorial Assistant
Novartis announced today that the FDA has granted three breakthrough therapy designations for Ilaris® (canakinumab) to treat rare types of Periodic Fever Syndromes, also known as Hereditary Periodic Fevers.